Amikacin therapy of gram-negative bacteremia.
Treatment with amikacin was evaluated in 15 patients with gram-negative bacteremia. The sources of sepsis were urinary tract (in six patients), abdomen (in five) and miscellaneous sites (in four). Sixteen bacterial pathogens were recovered, including three gentamicin-resistant organisms. All isolates were susceptible to amikacin. Eleven of the 14 patients who could be evaluated fulfilled the criteria for cure, including the three patients with gentamicin-resistant organisms. Three patients failed to respond to amikacin therapy. Monitoring untoward effects revealed eighth nerve toxicity in one patient and nephrotoxicity in one patient. These results indicate that amikacin is effective in the treatment of patients with gram-negative bacteremia, even when caused by gentamicin-resistant bacteria.
D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D005839:Gentamicins / Q000627:therapeutic use; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D018805:Sepsis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin